TENX Earnings & Financial Statements
Tenax Therapeutics, Inc.
$1.55
+$0.01(+0.65%)
30
Overall
60
Value
18
Tech
13
Quality
Market Cap
$57.45M
Volume
507.55K
52W Range
$1.31 - $19.40
Target Price
$13.38
TENX earnings and financial statements: Tenax Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
TENX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$56.38M | -$19.49M | -$8.23M | -$11.05M | -$32.73M |
| EBITDA | -$53.13M | -$17.67M | -$7.71M | -$10.93M | -$32.36M |
| Net income | -$52.60M | -$17.60M | -$7.71M | -$11.05M | -$32.47M |
| EPS (diluted) | $-1.34 | $-1.15 | $-31.04 | - | $-2528.00 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $104.23M | $96.69M | $11.69M | $3.40M | $5.99M |
| Total liabilities | $7.16M | $4.69M | $3.59M | $1.91M | $1.75M |
| Shareholders’ equity | $97.07M | $91.99M | $8.10M | $1.49M | $4.24M |
| Cash and equivalents | - | - | $9.80M | $2.12M | $5.58M |
| Long-term debt | - | - | - | $64.2K | $183.6K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$35.80M | -$14.80M | -$5.90M | -$11.39M | -$10.86M |
| Capital expenditure | - | - | $3.0K | -$2.3K | -$5.3K |
| Free cash flow | -$35.80M | -$14.80M | -$5.90M | -$11.39M | -$10.86M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TENX | $1.55 | +0.7% | 507.55K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Tenax Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW